A comparison of the effects and complications of transforaminal Triamcinolone and Dexmedetomidine in radicular low back pain.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201312037984N12

Enrollment

Registered

2017-09-15

Start date

2017-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic low back pain. low back pain

Interventions

Intervention 1: In intervention group 3 ml 0.2% Ropivacaine (Ropivacaina Molteni, Molteni, Italy) plus Dexmedetomidine 1 microgram per Kilogram (Precedex, Hospira, USA) was injected in the selected le

Treatment - Drugs

In intervention group 3 ml 0.2% Ropivacaine (Ropivacaina Molteni, Molteni, Italy) plus Dexmedetomidine 1 microgram per Kilogram (Precedex, Hospira, USA) was injected in the selected level by a curved

In control group 3 ml 0.2% Ropivacaine (Ropivacaina Molteni, Molteni, Italy) plus 20 mg Triamcinolone (Triamcinolone acetonide, EXIR, IRAN) was injected in the selected level by a curved blunt tip 10

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria Age 20-70 years; Pain that has not responded to treatment for at least 6 weeks; Evidence of Nerve root involvement as disc bulging and/or foraminal stenosis in CT/MRI; VAS > 4; ASA class I, II; Patients’ Informed consent Exclusion criteria: Patients with coagulopathy ; Infection in injection site as Herpetic diseases; Anatomical and congenital spine deformity as severe scoliosis; Surgical history instrument insertion; Psychological severe disorders; History of harmful reaction to local anesthetic and steroid; Patients with motor deficit or progressive neural defect; Cancer ; Neural foramen radiological access difficulty; Substance abuse; HIV; Acute trauma; Cauda Equina syndrome; More than 3 level abnormalities ;. Absence of radicular pain

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Low back pain. Timepoint: Before injection,two weeks,1,3 and 6 month after intervention. Method of measurement: pain score measured with visual analogue scale in Questionnaire.	—

Secondary

Measure	Time frame
Oswestry Disability Index questionnaire (ODI) and straight leg raising test (SLR), complications. Timepoint: Before injection, two weeks, 1,3 and 6 moth after intervention. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farnad Imani

Rasool Akram Medical Center

farnadimani@yahoo.com+98 21 6651 5758

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026